Toggle light / dark theme

CRISPR Dreams: The Potential for Gene Editing

Bonny Lemma. Originally published in the HIR Winter 2019 Issue.

Jennifer Lopez has one more industry to add to her illustrious résumé: molecular biology. In 2016, she was asked to be the executive producer of a new futuristic bio-crime drama for NBC called C.R.I.S.P.R. While that project is a work of science fiction, the CRISPR technology that it is based on is very real.

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is not just a gene editing technique, but also a phenomenon that carries significant implications for the future of biotechnology. Therefore, the interactions between the countless players in this field and the objectives driving them are crucial to understanding of CRISPR and the promise it holds.

“SuperAger” brains defy tau tangles associated with Alzheimer’s

Although the definitive causes of Alzheimer’s diseases aren’t yet fully understood, one of the leading suspects is the accumulation of abnormal proteins in the brain that impinges on the activity of the neurons. Scientists at Northwestern University have explored this phenomenon in a group of elderly individuals with excellent memory, known as SuperAgers, and found them to be far more resistant to the troublesome buildup of some of these proteins, shedding further light on how the disease may take hold.

A lot of the research into the progression of Alzheimer’s focus on a pair of proteins called amyloid and tau. Clumps of amyloid are thought to build up and develop into plaques that impact on memory and cognitive function, while tau takes the form of tangles that interfere with the way nutrients are taken up by the neurons, eventually leading to the death of the cell.

The Northwestern University researchers carried out experiments to study the prevalence of these proteins in SuperAgers, a group of subjects over the age of 80 with the memory capacity of someone 20 to 30 years younger than them. These subjects are assessed annually as part of ongoing research at Northwestern’s Mesulam Center for Cognitive Neurology and Alzheimer’s Disease.

The NIA Is Funding Clinical Trials Against Aging

Companies that are creating rejuvenation biotechnology interventions must develop their products to target individual diseases in order to be approved by the FDA. While that is still the case, this particular FOA is intended to promote broader research that does not necessarily target individual diseases as endpoints.


The National Institutes of Aging in the United States, a component of the National Institutes of Health, is funding clinical trials for interventions that directly affect the root causes of age-related diseases.

Direct funding for trials against aging

Probably the most important and interesting part of this Funding Opportunity Announcement (FOA) is that the NIA specifically mentions “multiple chronic conditions” caused by the processes of aging along with more conventional trials that are targeted directly at specific downstream effects of aging.

/* */